Zacks Investment Research cut shares of LifeMD (NASDAQ:LFMD) from a hold rating to a sell rating in a report issued on Wednesday, Zacks.com reports.

According to Zacks, “LifeMD Inc. is a telehealth company. It offers a full portfolio of direct-to-patient products and services. The company combines virtual medical treatment with prescription medications and unique over-the-counter products. Its network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers. LifeMD Inc., formerly known as Conversion Labs, is based in NEW YORK. “

LFMD stock opened at $16.25 on Wednesday. LifeMD has a 12-month low of $1.20 and a 12-month high of $33.02.

LifeMD (NASDAQ:LFMD) last released its quarterly earnings results on Sunday, March 28th. The company reported ($2.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($2.29).

In other LifeMD news, COO Brad Michael Roberts purchased 5,000 shares of the business’s stock in a transaction dated Thursday, February 25th. The shares were acquired at an average price of $20.50 per share, for a total transaction of $102,500.00.

LifeMD Company Profile

LifeMD, Inc operates as a telemedicine company with a portfolio of online direct-to-consumer brands. The company combines virtual medical treatment with prescription medications and over-the-counter products. Its network of physicians offers telemedicine services and direct-to-consumer pharmacy to consumers across the U.S.

Read More: Why Invest in High-Yield Dividend Stocks?

Get a free copy of the Zacks research report on LifeMD (LFMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for LifeMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeMD and related companies with MarketBeat.com's FREE daily email newsletter.